MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?
MOCA-2
1 other identifier
interventional
104
1 country
6
Brief Summary
This study concerns elderly patients with cancer with onco-geriatric assessment. This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the MoCA and the MMS tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. The results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2017
Longer than P75 for not_applicable
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 26, 2017
CompletedFirst Posted
Study publicly available on registry
October 3, 2017
CompletedStudy Start
First participant enrolled
October 13, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 13, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
October 13, 2023
CompletedOctober 18, 2023
September 1, 2023
6 years
September 26, 2017
October 17, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evaluate the sensitivity of MoCA test
MoCA is considered clinically relevant if its sensitivity to identify patients with cognitive impairment is at least 75%
Up 2 months after inclusion, before initiation of treatment
Interventions
Passation of MoCA and MMS tests associated with neuropsychological test
Eligibility Criteria
You may qualify if:
- Patient aged over 70 years
- Patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). Surgery and radiotherapy are allowed before entry into the study.
- Patient candidate for oncogeriatric assessment
- Patient agree to participate in the study
- Using the French language
You may not qualify if:
- Primary central nervous system or cerebral metastasis
- Evolutionary psychiatric pathology known (e.g. schizophrenia)
- Severe Visual and / or Auditory Impairment
- Patients unable to respond to cognitive tests
- Patient (s) deprived of liberty, under guardianship or curatorship
- Refusal of participation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (6)
Centre François Baclesse
Caen, France
CHU
Caen, France
CH
Cherbourg, France
Ch Compiegne
Compiègne, France
Centre Henri Becquerel
Rouen, France
Centre Hospitalier
Saint-Lô, France
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
florence JOLY, prof
Centre François Baclesse
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 26, 2017
First Posted
October 3, 2017
Study Start
October 13, 2017
Primary Completion
October 13, 2023
Study Completion
October 13, 2023
Last Updated
October 18, 2023
Record last verified: 2023-09
Data Sharing
- IPD Sharing
- Will not share